Masaaki Murakami

Masaaki Murakami

Auto-generated profile, based on publicly available information

Masaaki Murakami

Department of Nephrology, Shizuoka General Hospital, Shizuoka, Japan

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2015 in The Journal of Vascular Access
Verified
Journal Article
Closed access
MMMasaaki Murakami
Masaaki Murakami
MMMasahito Miyamoto
Masahito Miyamoto
KSKotaro Suemitsu
Kotaro Suemitsu
Purpose: Percutaneous transluminal angioplasty (PTA) is the first-line treatment for vascular access stenosis. To our knowledge, multicenter clinical research of PTA has not been reported in Japan. We examined the efficacy and safety of PTA for arteriovenous fistula (AVF) and arteriovenous graft (AVG) in five centers of Japan. Methods: Three hundred cases of angioplasty for AVF and 300 for AVG were examined in three centers each. A hundred consecutive patients from each center who underwent PTA for AVG or AVF prior to March 2014 and met the inclusion criteria were searched retrospectively. Primary patency rates were estimated using the Kaplan-Meier method. Results: The mean age was 69.3 ± 11.2 years in the AVF group and 70.2 ± 11.9 years in the AVG group. The anatomical success rates were 51.7% (155 of 300) in the AVF group and 72.0% (216 of 300) in the AVG group. The clinical success rates were 99.7% (299 of 300) in the AVF group and 100% (300 of 300) in the AVG group. A total of 25 complications (4.17%) were encountered in both groups including one major complication (0.17%). The primary patency was 99.0% at 1 month, 87.9% at 3 months and 51.7% at 6 months in the AVF group, and 96.0% at 1 month, 64.8% at 3 months and 20.4% at 6 months in the AVG group. Conclusions: The clinical success rate of PTA in five centers was relatively high and a major complication rate was only 0.17%. However, anatomical success rates were low comparing with the previous studies and the primary patency rates were inferior to the past data.

1 June 2021 in European Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Closed access
MMMasaaki Murakami
Masaaki Murakami
KMKiyoshi Mori
Kiyoshi Mori
SHSatoshi Hamanoue
Satoshi Hamanoue
KSKotaro Suemitsu
Kotaro Suemitsu
KKKengo Kajiwara
Kengo Kajiwara
MMMasashi Mukoyama
Masashi Mukoyama

23 January 2023 in Therapeutic Apheresis and Dialysis
Verified
Journal Article
Open access
HHHiroaki Haruguchi
Hiroaki Haruguchi
KSKotaro Suemitsu
Kotaro Suemitsu
NINaoko Isogai
Naoko Isogai
MMMasaaki Murakami
Masaaki Murakami
MFMasahiko Fujihara
Masahiko Fujihara
TIthe IN.PACT AV Access Investigators
the IN.PACT AV Access Investigators
Purpose: There is a lack of adjudicated and prospectively randomized published outcomes on the use of drug‐coated balloons (DCB) to treat dysfunctional arteriovenous fistula in Asian patients. This post hoc subgroup analysis of 112 Japanese participants from the global IN.PACT AV Access trial reports outcomes through 12 months.Materials and Methods: Participants were treated with DCB (n = 58) or standard non‐coated percutaneous transluminal angioplasty (PTA) balloons (n = 54). Outcomes included target lesion primary patency (TLPP), access circuit primary patency, and safety.Results: Through 6 months, TLPP was 86.0% (49/57) in the DCB group and 49.1% (26/53) in the PTA group (p < 0.001). Through 12 months, TLPP was 67.3% (37/55) in the DCB group and 43.4% (23/53) in the PTA group (p = 0.013).Conclusion: In this post hoc analysis of Japanese participants from the IN.PACT AV Access trial, participants treated with DCB had higher TLPP through 6 and 12 months compared with PTA.

1 February 2017 in Journal of Vascular Surgery
Verified
Journal Article
Closed access
MMMasaaki Murakami
Masaaki Murakami
GSGenichi Sakaguchi
Genichi Sakaguchi
NMNoriko Mori
Noriko Mori

13 May 2024 in Journal of Vascular Surgery
Verified
Journal Article
Closed access
KMKeisuke Morita
Keisuke Morita
MMMasaaki Murakami
Masaaki Murakami
RARyota Akagi
Ryota Akagi
KNKojiro Nagai
Kojiro Nagai

14 October 2024 in The Journal of Vascular Access
Verified
Journal Article
Open access
HHHiroaki Haruguchi
Hiroaki Haruguchi
MFMizuya Fukasawa
Mizuya Fukasawa
KIKiyoshi Ikeda
Kiyoshi Ikeda
KSKotaro Suemitsu
Kotaro Suemitsu
TSTakashi Sato
Takashi Sato
KAKiyoshi Aikawa
Kiyoshi Aikawa
Purpose: To assess 6-month safety and efficacy of a self-expanding stent graft placement to treat stenotic or thrombosed synthetic arteriovenous access graft at the venous anastomoses. Material and methods: This prospective, multicenter, post-market surveillance study assessed the GORE ® VIABAHN ® Endoprosthesis (stent graft) in Japanese patients with stenotic or thrombosed vascular access grafts. Key efficacy and safety outcomes were primary patency (PP) and secondary patency (SP) of the target lesion and the vascular access circuit, repeat interventions, technical and clinical success, incidence of adverse and serious adverse events, and device deficiencies through 6 months. Results: The 103 enrolled patients (mean age 71.8 years; 57.3% female) had stent grafts placed in the venous anastomosis of arteriovenous access grafts (on-label). The majority of lesions were stenotic (77.1%) and located in the upper arm (91.4%). Mean lesion length was 42.9 ± 23.6 mm and diameter was 6.7 ± 1.9 mm; 28 patients (27.2%) had elephant trunk placements. Technical and clinical success rates were 100%. At 6 months, Kaplan-Meier estimates of target lesion and circuit PP were 75.1% (95% CI: 65.2, 82.6) and 66.8% (95% CI: 56.4, 75.3), and SP rates were 93.8% (95% CI: 86.7, 97.2) and 93.8% (95% CI: 86.7, 97.2), respectively. Mean cumulative number of reinterventions (0.36; 95% CI: 0.20, 0.51) and incidence of device- or procedure-related adverse events were low (⩽3%). No device deficiencies were reported. Conclusions: The 6-month outcomes of the self-expanding stent graft to treat thrombosed venous anastomoses of synthetic hemodialysis vascular access grafts with stenosis demonstrated safety and effectiveness.